Cost-effectiveness of bedaquiline, pretomanid and linezolid for treatment of extensively drug-resistant tuberculosis in South Africa, Georgia and the Philippines
Objectives Patients with highly resistant tuberculosis have few treatment options. Bedaquiline, pretomanid and linezolid regimen (BPaL) is a new regimen shown to have favourable outcomes after six months. We present an economic evaluation of introducing BPaL against the extensively drug-resistant tu...
Saved in:
| Main Authors: | Francesca Conradie, Anna Vassall, Norbert Ndjeka, Gabriela Beatriz Gomez, Mariana Siapka, Anna Marie Celina Garfin, Nino Lomtadze, Zaza Avaliani, Nana Kiria, Shelly Malhotra, Sarah Cook-Scalise, Sandeep Juneja, Daniel Everitt, Melvin Spigelman |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2021-12-01
|
| Series: | BMJ Open |
| Online Access: | https://bmjopen.bmj.com/content/11/12/e051521.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Bedaquiline, pretomanid, linezolid, and moxifloxacin (BPaLM) for multidrug- or rifampin-resistant tuberculosis: a systematic review
by: Denise Rossato Silva, et al.
Published: (2025-01-01) -
Linking genetic and phenotypic bedaquiline resistance in Mycobacterium tuberculosis strains from Georgia.
by: Nino Maghradze, et al.
Published: (2025-01-01) -
Linking genetic and phenotypic bedaquiline resistance in Mycobacterium tuberculosis strains from Georgia
by: Nino Maghradze, et al.
Published: (2025-01-01) -
Parameters of Complete Blood Count and Blood Chemistry during Treatment of Patients with MDR/XDR Pulmonary Tuberculosis with a Short-Course Regimen Containing Bedaquiline, Pretomanid, and Linezolid
by: R. Yu. Abdullaev, et al.
Published: (2023-08-01) -
Assessing the Impact of Bedaquiline, Clofazimine, and Linezolid on Mycobacterial Genome Integrity
by: Dániel Molnár, et al.
Published: (2024-11-01)